Bioxytran, Inc.
BIXT
$0.03
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 92.47% | -34.08% | -41.57% | -58.37% | -45.48% |
| Depreciation & Amortization | 50.00% | 45.57% | 30.68% | -3.30% | -20.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.37% | -16.90% | -37.00% | -53.37% | -48.82% |
| Operating Income | -66.37% | 16.90% | 37.00% | 53.37% | 48.82% |
| Income Before Tax | 10.17% | 10.79% | 12.19% | 28.49% | 25.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.17% | 10.79% | 12.19% | 28.49% | 25.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -100.00% | -100.00% |
| Net Income | 10.17% | 10.29% | 11.02% | 27.01% | 24.04% |
| EBIT | -66.37% | 16.90% | 37.00% | 53.37% | 48.82% |
| EBITDA | -66.45% | 17.12% | 37.21% | 53.50% | 48.89% |
| EPS Basic | 12.29% | -26.78% | -51.74% | -16.59% | -1.01% |
| Normalized Basic EPS | 15.12% | -10.00% | -57.39% | -23.29% | -6.22% |
| EPS Diluted | 12.29% | -26.78% | -51.74% | -16.59% | -1.01% |
| Normalized Diluted EPS | 15.12% | -10.00% | -57.39% | -23.29% | -6.22% |
| Average Basic Shares Outstanding | -19.41% | -34.35% | -41.43% | -36.38% | -15.88% |
| Average Diluted Shares Outstanding | -19.41% | -34.35% | -41.43% | -36.38% | -15.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |